What is Multi-Parametric MRI (mpMRI)?
Multi-parametric MRI (mpMRI) is a specialized prostate imaging technique that combines high-resolution T2-weighted sequences with functional imaging sequences—specifically diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging—to detect, localize, and characterize clinically significant prostate cancer. 1, 2
Core Components of mpMRI
The technique integrates three essential imaging sequences:
T2-weighted (T2W) imaging: Provides high-resolution anatomical detail of prostate structure and is particularly important for evaluating the transition zone 1
Diffusion-weighted imaging (DWI): Assesses tissue cellularity and is the primary sequence for evaluating the peripheral zone; higher-grade cancers typically show restricted diffusion 1
Dynamic contrast-enhanced (DCE) imaging: Evaluates vascular properties and perfusion patterns; in the current PI-RADS v2 system, DCE plays a clarification role primarily for peripheral zone assessments rather than a primary diagnostic role 1
Important note: Earlier versions included magnetic resonance spectroscopy (MRS), but PI-RADS v2 eliminated this component to simplify the protocol and reduce variability 1.
Clinical Purpose and Applications
mpMRI serves multiple critical functions in prostate cancer management:
Detection and localization: mpMRI increases diagnostic yield for clinically significant prostate cancer (Gleason score ≥3+4) while reducing detection of insignificant disease 1. The technique can detect index lesions with primary Gleason score ≥3+4 and volume ≥0.2 ml (approximately 7-8 mm diameter) on modern 3-Tesla scanners 1.
Biopsy guidance: The imaging allows targeted biopsies to suspicious lesions, improving detection rates while using fewer biopsy cores 1. This addresses the limitation of random systematic biopsies that may miss significant cancers.
Active surveillance: According to updated PRECISE v2 recommendations, mpMRI plays a standardized role in monitoring patients on active surveillance, with specific protocols for baseline and follow-up imaging 3.
Standardized Reporting: PI-RADS
The Prostate Imaging-Reporting and Data System version 2 (PI-RADS v2) provides standardized assessment categories (1-5) that summarize the likelihood of clinically significant prostate cancer 1. This system was developed jointly by the American College of Radiology, European Society of Urogenital Radiology, and AdMeTech Foundation to reduce interpretation variability and standardize reporting 1.
Critical caveat: PI-RADS scores indicate probability, not certainty. A PI-RADS 2 lesion does not completely exclude clinically significant cancer—it indicates it is unlikely. Similarly, PI-RADS 5 indicates high likelihood but is not definitive proof 1.
Technical Considerations
mpMRI quality depends on multiple factors including equipment capabilities (magnet field strength, coil configuration), patient factors (body habitus, motion, rectal gas), and critically, radiologist expertise and interpretation 1. This variability has necessitated the development of quality standards and accreditation requirements for centers performing prostate mpMRI 1.
The technique deliberately prioritizes detection of clinically significant disease over detection of all prostate cancers, with intentionally lower sensitivity for low-volume Gleason 3+3 disease (<0.5 ml), which is unlikely to cause patient harm 1.